| Name | Section 216: Advanced Pharmacogenomics for CBS/PSP |
| Summary | Advanced pharmacogenomics for CBS/PSP treatment: CYP2D6/CYP3A4 variants affecting levodopa/rasagiline metabolism, APOE genotyping, NET assessment, genetic predictors of drug response, personalized dosing, drug-gene interactions, clinical implementation |